AR128825A1 - Composiciones farmacéuticas de esfingomielinasa ácida humana recombinante y métodos - Google Patents
Composiciones farmacéuticas de esfingomielinasa ácida humana recombinante y métodosInfo
- Publication number
- AR128825A1 AR128825A1 ARP230100671A ARP230100671A AR128825A1 AR 128825 A1 AR128825 A1 AR 128825A1 AR P230100671 A ARP230100671 A AR P230100671A AR P230100671 A ARP230100671 A AR P230100671A AR 128825 A1 AR128825 A1 AR 128825A1
- Authority
- AR
- Argentina
- Prior art keywords
- rasm
- methods
- acid sphingomyelinase
- chromatography
- cex
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 101000785978 Homo sapiens Sphingomyelin phosphodiesterase Proteins 0.000 title 1
- 102000048866 human SMPD1 Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 7
- 238000005277 cation exchange chromatography Methods 0.000 abstract 4
- 238000001597 immobilized metal affinity chromatography Methods 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 208000034012 Acid sphingomyelinase deficiency Diseases 0.000 abstract 2
- 102000001708 Protein Isoforms Human genes 0.000 abstract 2
- 108010029485 Protein Isoforms Proteins 0.000 abstract 2
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 abstract 2
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 abstract 2
- 238000004587 chromatography analysis Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000011210 chromatographic step Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
- B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
- B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
- B01D15/203—Equilibration or regeneration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263321636P | 2022-03-18 | 2022-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128825A1 true AR128825A1 (es) | 2024-06-19 |
Family
ID=86051983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100671A AR128825A1 (es) | 2022-03-18 | 2023-03-17 | Composiciones farmacéuticas de esfingomielinasa ácida humana recombinante y métodos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230365946A1 (https=) |
| EP (1) | EP4493684A1 (https=) |
| JP (1) | JP2025509722A (https=) |
| KR (1) | KR20240156645A (https=) |
| CN (1) | CN119365593A (https=) |
| AR (1) | AR128825A1 (https=) |
| AU (1) | AU2023235321A1 (https=) |
| CA (1) | CA3254814A1 (https=) |
| IL (1) | IL315655A (https=) |
| MX (1) | MX2024011382A (https=) |
| TW (1) | TW202403043A (https=) |
| WO (1) | WO2023178325A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4594462A1 (en) | 2022-09-28 | 2025-08-06 | Genzyme Corporation | Systems and devices for producing biological products and methods of using the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| US5773278A (en) | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
| US20020137173A1 (en) * | 2001-02-05 | 2002-09-26 | Dae-Kyong Kim | Membrane-associated sphingomyelinase derived from bovine brain, isolation method therefor and anti-sphingomyelinase monoclonal anitibody |
| US7527956B2 (en) * | 2003-06-12 | 2009-05-05 | Genzyme Corporation | Modified human acid sphingomyelinase having increased activity, and methods for making the same |
| WO2008085988A1 (en) | 2007-01-05 | 2008-07-17 | Amgen Inc. | Methods of purifying proteins |
| KR20100103595A (ko) | 2008-01-18 | 2010-09-27 | 에프. 호프만-라 로슈 아게 | 비-글라이코실화된 단백질의 정제 |
| RU2012151132A (ru) | 2010-05-19 | 2014-06-27 | Ф. Хоффманн-Ля Рош Аг | Хроматография с гиброфобным взаимодействием |
| AR082319A1 (es) * | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos |
| EP2997036B1 (en) | 2013-05-15 | 2021-03-03 | Medimmune Limited | Purification of recombinantly produced polypeptides |
| DK3728287T3 (da) | 2017-12-19 | 2024-06-10 | CSL Behring Lengnau AG | Proteinoprensning og virusinaktivering med alkylglycosider |
| PY1939780A (es) | 2018-05-25 | 2019-12-04 | Genzyme Corp | Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida |
-
2023
- 2023-03-16 TW TW112109733A patent/TW202403043A/zh unknown
- 2023-03-17 WO PCT/US2023/064657 patent/WO2023178325A1/en not_active Ceased
- 2023-03-17 IL IL315655A patent/IL315655A/en unknown
- 2023-03-17 KR KR1020247034621A patent/KR20240156645A/ko active Pending
- 2023-03-17 CN CN202380028273.4A patent/CN119365593A/zh active Pending
- 2023-03-17 AR ARP230100671A patent/AR128825A1/es unknown
- 2023-03-17 JP JP2024555092A patent/JP2025509722A/ja active Pending
- 2023-03-17 CA CA3254814A patent/CA3254814A1/en active Pending
- 2023-03-17 AU AU2023235321A patent/AU2023235321A1/en active Pending
- 2023-03-17 EP EP23717785.2A patent/EP4493684A1/en active Pending
- 2023-03-17 MX MX2024011382A patent/MX2024011382A/es unknown
- 2023-03-20 US US18/186,731 patent/US20230365946A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025509722A (ja) | 2025-04-11 |
| TW202403043A (zh) | 2024-01-16 |
| WO2023178325A1 (en) | 2023-09-21 |
| IL315655A (en) | 2024-11-01 |
| KR20240156645A (ko) | 2024-10-30 |
| US20230365946A1 (en) | 2023-11-16 |
| CA3254814A1 (en) | 2023-09-21 |
| AU2023235321A1 (en) | 2024-10-31 |
| MX2024011382A (es) | 2024-09-23 |
| CN119365593A (zh) | 2025-01-24 |
| EP4493684A1 (en) | 2025-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gutiérrez et al. | Pharmacological activities of a toxic phospholipase A isolated from the venom of the snake Bothrops asper | |
| Erlanson et al. | Purification and characterization of two proteins with co-lipase activity from porcine pancreas | |
| Rifas et al. | Human osteoblasts in vitro secrete tissue inhibitor of metalloproteinases and gelatinase but not interstitial collagenase as major cellular products. | |
| Rodrigues et al. | Geographic variations in the composition of myotoxins from Bothrops neuwiedi snake venoms: biochemical characterization and biological activity | |
| Boucek | Factors affecting wound healing | |
| Kanashiro et al. | Biochemical and biological properties of phospholipases A2 from Bothrops atrox snake venom | |
| Wahby et al. | Egyptian horned viper Cerastes cerastes venom hyaluronidase: Purification, partial characterization and evidence for its action as a spreading factor | |
| Suttie | The metabolic role of vitamin K | |
| AR128825A1 (es) | Composiciones farmacéuticas de esfingomielinasa ácida humana recombinante y métodos | |
| Kumar et al. | Heparin‐binding proteins of human seminal plasma: purification and characterization | |
| EP0354354B1 (de) | Verfahren zur Anreicherung der Blutgerinnungsfaktoren II, VII, IX und X | |
| Duplat et al. | The effect of molecules in mother-of-pearl on the decrease in bone resorption through the inhibition of osteoclast cathepsin K | |
| Venkatesh et al. | Synergistically acting PLA2: Peptide hemorrhagic complex from Daboia russelii venom | |
| KR101853463B1 (ko) | 보툴리눔 독소의 정제 방법 | |
| JPH06107693A (ja) | 蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法 | |
| AR042019A1 (es) | N-acetilgalactosamina-4-sulfatasa precursora, composiciones farmaceuticas que la contienen , metodos de tratamiento que la utilizan y metodos para producirla y purificarla | |
| Lomonte et al. | Antibody neutralization of a myotoxin from the venom of Bothrops asper (terciopelo) | |
| Shashidharamurthy et al. | A neurotoxic phospholipase A2 variant: Isolation and characterization from eastern regional Indian cobra (Naja naja) venom | |
| JP2025509722A5 (https=) | ||
| Suttie et al. | Postribosomal function of vitamin K in prothrombin synthesis | |
| DE69009668T2 (de) | Verfahren zur herstellung von aktiviertem protein c. | |
| JPS59155324A (ja) | ヒト尿中チオ−ルプロテア−ゼインヒビタ−を有効成分とする抗炎症剤及びその製造法 | |
| Nakayama et al. | Characteristics of Prolidase from the Erythrocytes of Normal Humans and Patients with Prolidase Deficiency and Their Mother. | |
| JP3400367B2 (ja) | 精製された新規精巣上体前進運動能タンパク質および稔性促進因子／抑制因子として有用な前記タンパク質の精製方法 | |
| US6316602B1 (en) | Beta taipoxin as a cell growth factor and method |